Breast Cancer (HR+HER2-)
1 clinical trials · Condition
◉ Watch Breast Cancer (HR+HER2-)
| Record | Firm | Date |
|---|---|---|
| A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (NCT02791334) | Eli Lilly and Company | 2016-06-29 |
Track Breast Cancer (HR+HER2-) automatically
Every clearance here is in the API, with alerts when new ones post.